Health Discoveries in General Health News

Hallucinogenic drug study focuses on cancer patient anxiety

October 26, 2010

A recent study on a hallucinogenic drug found that it may reduce anxiety in patients with advanced-stage cancer, according to the Archives of General Psychiatry.

A research team at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center found that psilocybin, last tested in the 1960s for its beneficial effect on moods and anxiety, improved the moods of 12 cancer patients for up to six months following treatment.

Previous research on psychedelic drugs was shut down in the early 1970s when the drugs became popular for recreational use and led to stricter laws regulating them.

"Political and cultural pressures forced an end to these studies in the 1970s," said Dr. Charles Grob, who led the research team. "We were able to revive this research under strict federal supervision and demonstrate that this is a field of study with great promise for alleviating anxiety and other psychiatric symptoms."

One of the rehabilitation programs for cancer patients at the North Shore University Hospital in Manhasset, New York, is the Lebed Method of exercise for women who have been treated for breast cancer. The program helps women maintain range of motion, reduce the risk of lymphedema, decrease depression and provide mutual support. The hospital is part of the North Shore-LIJ Health System.

  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Hallucinogenic drug study focuses on cancer patient anxiety :